Itacitinib adipate is a selective Janus kinase 1 (JAK1) inhibitor primarily used in oncology and immunology. It is investigated for the treatment of myelofibrosis and other myeloproliferative neoplasms driven by JAK pathway dysregulation. By inhibiting JAK signaling, it modulates immune responses, reduces inflammation, and targets aberrant cell proliferation in these disorders. It is also in clinical trials for preventing acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation, where it helps manage immune-mediated complications. Additionally, it shows potential in combination therapies to enhance anticancer treatments by suppressing interfering immune responses, and in autoimmune conditions like rheumatoid arthritis.